Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND It is estimated that 5% of patients with sarcoidosis have clinically manifest cardiac involvement, although autopsy and imaging studies suggest a significantly higher prevalence of cardiac involvement. There is a paucity of contemporary data on the risk of adverse cardiac outcomes, particularly heart failure (HF), in patients with sarcoidosis. OBJECTIVES The purpose of this study was to examine the long-term risk of HF and other adverse cardiac outcomes in patients with sarcoidosis compared with matched control subjects. METHODS In this cohort study, all patients age ≥18 years with newly diagnosed sarcoidosis (1996 to 2016) were identified through Danish nationwide registries and matched 1:4 by age, sex, and comorbidities with control subjects from the background population without sarcoidosis. RESULTS Of the 12,042 patients diagnosed with sarcoidosis, 11,834 patients were matched with 47,336 subjects from the background population (median age: 42.8 years [25th to 75th percentile: 33.1 to 55.8 years], 54.3% men). The median follow-up was 8.2 years. Absolute 10-year risks of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosis patients and 1.72% (95% CI: 1.58% to 1.86%) for the background population; the composite of ICD implantation, ventricular arrhythmias, and cardiac arrest: 0.96% (95% CI: 0.77% to 1.18%) for sarcoidosis patients and 0.45% (95% CI: 0.38% to 0.53%) for the background population; the composite of pacemaker implantation, atrioventricular block, and sinoatrial dysfunction: 0.94% (95% CI: 0.75% to 1.16%) for sarcoidosis patients and 0.51% (95% CI: 0.44% to 0.59%) for the background population; atrial fibrillation or flutter: 3.44% (95% CI: 3.06% to 3.84%) for sarcoidosis patients and 2.66% (95% CI: 2.49% to 2.84%) for the background population; and all-cause mortality: 10.88% (95% CI: 10.23% to 11.55%) for sarcoidosis patients and 7.43% (95% CI: 7.15% to 7.72%) for the background population. CONCLUSIONS Patients with sarcoidosis had a higher associated risk of HF and other adverse cardiac outcomes compared with matched control subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citation2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
The Danish National Patient Register
Lynge, E., Sandegaard, J. L., & Rebolj, M. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494811401482 · Cited by 3,968
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8807 · Cited by 3,304
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Roger, V. L. (2013) · Circulation Research · doi:10.1161/circresaha.113.300268 · Cited by 1,728
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationValeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
Racial Differences in Sarcoidosis Incidence: A 5-Year Study in a Health Maintenance Organization
Rybicki, B. A., Major, M., Popovich, J., Maliank, M. J., & lannuzzi, M. C. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009096 · Cited by 1,011
Roberts, W. C., McAllister, H. A., & Ferrans, V. J. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90121-8 · Cited by 789
Cited by
Cheng, R. K., Kittleson, M. M., Beavers, C. J., Birnie, D. H., Blankstein, R., Bravo, P. E., Gilotra, N. A., Judson, M. A., Patton, K. K., Rose-Bovino, L., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001240 · Cited by 259
Gilotra, N. A., GRIFFIN, J. M., PAVLOVIC, N., HOUSTON, B. A., CHASLER, J., GOETZ, C., CHRISPIN, J., SHARP, M., KASPER, E. K., CHEN, E. S., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.06.016 · Cited by 94
Cheng, C.-Y., Baritussio, A., Giordani, A. S., Iliceto, S., Marcolongo, R., & Caforio, A. L. P. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103037 · Cited by 56
Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis
Mathai, S. V., Patel, S., Jorde, U. P., & Rochlani, Y. (2022) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcvj.1057 · Cited by 38
Tan, J. L., Tan, B. E.-X., Cheung, J. W., Ortman, M., & Lee, J. Z. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.04.007 · Cited by 34
Metadata
- Authors
- Yafasova, A., Fosbøl, E. L., Schou, M., Gustafsson, F., Rossing, K., Bundgaard, H., Lauridsen, M. D., Kristensen, S. L., Torp-Pedersen, C., Gislason, G. H., Køber, L., & Butt, J. H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 76
- Issue
- 7
- Pages
- 767-777
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3048299801
- Cited by
- 104
- References
- 10
- FWCI
- 7.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.